Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489086 · ClinicalTrials.gov registry record · Phase 2
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase 2 study of Neoplastic Syndrome, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT00489086: Completed Phase 2 study of Neoplastic Syndrome, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT00489086 is a Phase 2 study of Neoplastic Syndrome that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 36 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00489086, a Phase 2 study of Neoplastic Syndrome, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.
Conditions Studied
Interventions
- DRUG tazarotene
Study Locations (2)
California
- Children's Hospital and Research Center Oakland - Oakland
New York
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-07 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00489086
The ClinicalTrials.gov registry entry for NCT00489086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplastic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which tazarotene is the first listed.
NCT00489086 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT00489086 about?
NCT00489086 is a clinical study titled "Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face". RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal ce...
What is the current status of trial NCT00489086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-07. Estimated completion is 2012-06.
What conditions does trial NCT00489086 study?
This clinical trial studies the following conditions: Neoplastic Syndrome.
What interventions are being tested in trial NCT00489086?
The interventions under investigation include: tazarotene (DRUG).
Who is sponsoring clinical trial NCT00489086?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489086 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.